1. Dual targeting, a new strategy for novel PARP inhibitor discovery
   Lina Wei et al, 2021, Drug Discoveries & Therapeutics CrossRef
2. ARID1A mutation associated with recurrence and shorter progression-free survival in atypical meningiomas
   Danielle Chaluts et al, 2023, Journal of Cancer Research and Clinical Oncology CrossRef
3. The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?
   Shouying Xu et al, 2021, Frontiers in Oncology CrossRef
4. DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive Review
   Menghui Wang et al, 2022, Frontiers in Genetics CrossRef
5. Role of AT‐rich interaction domain 1A in gastric cancer immunotherapy: Preclinical and clinical perspectives
   Xuemei Zhang et al, 2024, Journal of Cellular and Molecular Medicine CrossRef
6. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma
   Supharada Tessiri et al, 2022, PeerJ CrossRef
7. Targeting Signaling Pathway Networks in Several Malignant Tumors: Progresses and Challenges
   Hongdan He et al, 2021, Frontiers in Pharmacology CrossRef
8. The BAF chromatin remodeling complexes: structure, function, and synthetic lethalities
   Julia Varga et al, 2021, Biochemical Society Transactions CrossRef
9. The Atypical Protein Kinase C Small Molecule Inhibitor ζ-Stat, and Its Effects on Invasion Through Decreases in PKC-ζ Protein Expression
   Tracess Smalley et al, 2020, Frontiers in Oncology CrossRef
10. SWI/SNF chromatin remodeling complex alterations in meningioma
    Corey M. Gill et al, 2021, Journal of Cancer Research and Clinical Oncology CrossRef
11. PARP inhibitors in gastric cancer: beacon of hope
    Yali Wang et al, 2021, Journal of Experimental & Clinical Cancer Research CrossRef